Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247511 | 0.92 | LTA4H (0.57) | TDP1CARM1PRMT6PARP15PARP10 | |
| SCHEMBL10533845 | 0.91 | PARP15 (0.56) | TDP1CARM1PRMT6PARP15PARP10 | |
| SCHEMBL8284686 | 0.90 | PARP15 (0.50) | TDP1CARM1PRMT6PARP15PARP10 | |
| SCHEMBL14451432 | 0.90 | PARP15 (0.50) | TDP1CARM1PRMT6PARP15PARP10 | |
| SCHEMBL8356592 | 0.89 | PARP15 (0.57) | TDP1CARM1PRMT6PARP15PARP10 | |
| Hydrochloric Acid SCHEMBL5521261 | 0.88 | HTR2C (0.49) | TDP1CARM1PRMT6PARP15PARP10 | |
| Hydrochloric Acid SCHEMBL5519191 | 0.88 | HTR2C (0.49) | TDP1CARM1PRMT6PARP15PARP10 | |
| Hydrochloric Acid SCHEMBL3037709 | 0.88 | PARP15 (0.49) | TDP1CARM1PRMT6PARP15PARP10 | |
| Hydrochloric Acid SCHEMBL3037711 | 0.88 | PARP15 (0.49) | TDP1CARM1PRMT6PARP15PARP10 | |
| SCHEMBL29024848 | 0.87 | PARP15 (0.64) | TDP1PARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114689792-B | Human olfactory working memory test method and device | 中国科学院脑科学与智能技术卓越创新中心 | 2023-10-24 | — | — | CN | claimed |
| CN-114689792-A | Human olfactory work memory testing method and device | 中国科学院脑科学与智能技术卓越创新中心 | 2022-07-01 | — | — | CN | claimed |
| CN-119584860-A | Comprising biodegradable microcapsule composition | 奇华顿股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119546194-A | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240228800-A1 | COATING MATERIAL, COATING LAYER, AND LIGHT-EMITTING DEVICE | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2024-07-11 | — | — | US | disclosed |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20240019781-A1 | DISPERSION RESIN, PREPARATION METHOD THEREFOR AND PHOTORESIST COMPOSITION | Shenzhen Brthrborder Semiconductor Materials Co., Ltd. (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-117015593-A | Use of enzymes for improving fragrance deposition | 诺维信公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-114689792-B | Human olfactory working memory test method and device | 中国科学院脑科学与智能技术卓越创新中心 | 2023-10-24 | — | — | CN | disclosed |
| US-20230151023-A1 | PYRIDO[2,3-E]OXAZINE DERIVATIVES AS AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230141042-A1 | FLUX RESIN COMPOSITION, ELECTRONIC COMPONENT, METHOD FOR MANUFACTURING THE ELECTRONIC COMPONENT, MOUNTING STRUCTURE, AND METHOD FOR MANUFACTURING THE MOUNTING STRUCTURE | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20070149726-A1 | CURABLE COMPOSITIONS HAVING IMPROVED ADHESION PERFORMANCE | HENKEL AG & CO. KGAA (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149726-A1 | CURABLE COMPOSITIONS HAVING IMPROVED ADHESION PERFORMANCE | HENKEL AG & CO. KGAA (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| CN-1505613-A | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents | ʷ��˿�������ȳ�ķ����˾ | 2004-06-16 | — | — | CN | disclosed |
| CN-1152864-C | Phenylphenanthridines with PDE-IV inhibiting activity | ��̹��ҽҩ��˾ | 2004-06-09 | — | — | CN | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| US-4962203-A | ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROST CANADA, INC. (CA) | 1990-10-09 | — | — | US | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | TDP1 3055/4885CARM1 1751/4885PRMT6 1008/4885 |
| US-20230151023-A1 | PYRIDO[2,3-E]OXAZINE DERIVATIVES AS AGRICULTURAL CHEMICALS | PNPO, HPD, PDXK | TDP1 2588/4885CARM1 4383/4885PRMT6 4262/4885 |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | HPGDS, MYADM, ACR | TDP1 2947/4885CARM1 3228/4885PRMT6 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.